- H1 FY2025 revenue of RM484.52 million up 17.8% year-on-year
- PBT and PAT for H1 FY2025 increase 43.4% compared to last year, with contribution from 21.0% year-on-year profit growth in Q2 FY2025
- Interim dividend of 1.5 sen per share announced, up 50% from the previous year
Kuala Lumpur, 21 August 2025 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) recorded revenue growth in the second quarter ended 30 June 2025, with H1 FY2025 revenue of RM484.52 million increasing 17.8% from the first half last year, supported by Q2 FY2025 revenue of RM221.78 million.
Meanwhile, profit before tax (PBT) and profit after tax (PAT) for Q2 FY2025 stood at RM26.58 million and RM20.20 million respectively, up 21.0% from Q2 FY2024. The profit results from Q2 FY2025 boosted the cumulative profits in H1 FY2025, whereby the respective PBT of RM60.32 million and PAT of RM45.84 million recorded were 43.4% higher than the cumulative first half profits in FY2024.
Leonard Ariff Abdul Shatar, Group Managing Director of Duopharma Biotech Berhad, commented, “Duopharma Biotech’s latest results were driven by strong sales performance across all business segments, particularly the increased sales to the public sector and a one-off surge in insulin supply during the first quarter, as the Group fulfilled outstanding orders following supply normalisation. Looking ahead, we foresee a favourable environment for industry players driven by Government policies and an ageing population sustaining demand for medical supplies, while a growing number of health-conscious Malaysians are purchasing nutrition products. We are encouraged to see the alignment between the immediate fiscal measures in Budget 2025 and the medium-term priorities under the 13th Malaysia Plan (RMK-13), reflecting a cohesive national agenda that prioritises healthcare reform, supports domestic manufacturing, and encourages greater self-reliance in medical and pharmaceutical supply chains.”
He noted that the pharmaceutical sector had been included as a Key Growth Segment in the New Industrial Master Plan 2030 (NIMP 2030) while the recently announced RMK-13 allocates a substantial RM40 billion for healthcare, encompassing infrastructure upgrades, expanding access to care, and supporting pharmaceutical research and manufacturing.
Currently, subsidiaries of Duopharma Biotech hold a total of 18 Letters of Offer (LOO) to supply a total of 100 products in the Approved Products Purchase List (APPL) to the Ministry of Health Malaysia’s facilities until 31 December 2026, at a combined estimated contract value of approximately RM684.15 million. The Company is also contracted to supply Insugen-Insulin Recombinant Human Formulations to the Ministry of Health Malaysia until 28 October 2025.
“In addition, the recent reduction in the OPR is expected to benefit the Group over the longer term, cushioning unfavourable impacts that may arise from the new electricity tariff and the expansion of the Sales and Service Tax. We are continuing to focus on enhancing operational efficiencies, strengthening cost discipline, and adapting to evolving market conditions to ensure the Group remains resilient and competitive in the industry,” Leonard Ariff added.
The Board of Directors announced an interim dividend of 1.5 sen per share for the current financial period ended 30 June 2025, amounting to approximately RM14.43 million, a notable 50% increase from the 1.0 sen per share interim dividend (equivalent to approximately RM9.62 million), announced in the corresponding period last year. The entitlement date and payment date have been determined for 9 September 2025 and 24 September 2025 respectively.
Reinforcing industry prominence
Recently, Duopharma Biotech achieved another milestone in Halal pharmaceuticals when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
The Company also continued to showcase the nation’s excellence in halal pharmaceuticals on the world stage, when wholly-owned subsidiary Duopharma (M) Sdn Bhd participated in KUSKOP Week hosted by the Ministry of Entrepreneur and Co- operatives Development (KUSKOP) and SME Bank at the Malaysia Pavilion during the recent World Expo 2025 in Osaka, Japan supporting Malaysia’s visibility in the global healthcare arena.
In addition, Duopharma Biotech’s ESG efforts were recognised for a third consecutive year at the Sustainability & CSR Malaysia Awards when it won two awards at the 10th Sustainability & CSR Malaysia Awards 2025, namely the Company of the Year (Pharmaceutical Manufacturing) – ESG Leadership Award and the Company of the Year – Long Standing Excellence Award.